SCHEMBL1401294

SCHEMBL1401294

CCCCCCN([C]=O)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 7/20 0.41
PPARG P37231 7/20 0.41
PPARD Q03181 7/20 0.41
PPARA Q07869 7/20 0.41
HDAC11 Q96DB2 5/20 0.41
TSHR P16473 4/20 0.41
PTPN1 P18031 3/20 0.41
ALDH1A1 P00352 2/20 0.41
TLR2 O60603 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
FABP4 P15090 2/20 0.41
SLC22A6 Q4U2R8 1/20 0.41
SLC22A8 Q8TCC7 1/20 0.41
MEN1 O00255 1/20 0.41
ESR1 P03372 1/20 0.41
ALOX15 P16050 1/20 0.41
PDE4A P27815 1/20 0.41
KMT2A Q03164 1/20 0.41
PDE3A Q14432 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1400991 0.98 AKR1B1 (0.39) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL1400993 0.91 CA12 (0.40) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL10925540 0.83 DNM1 (0.39) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL1401104 0.82
SCHEMBL10954933 0.82 ZDHHC20 (0.45) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL7686630 0.79 CES2 (0.34) GPR84MEN1KMT2AEPHX2DNM1
SCHEMBL8253430 0.79 ZDHHC20 (0.42) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL965005 0.79 EPHX1 (0.39) EPHX2DNM1ZDHHC20
SCHEMBL11517386 0.77 DNM1 (0.38) ALDH1A1MEN1ESR1KMT2AMAPT
SCHEMBL11517198 0.77 DNM1 (0.38) ALDH1A1MEN1ESR1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103337-A1 MEDICINE FOR IMPROVING STATE OF PREGNANCY, AND USE THEREOF Yamaguchi, Koushi (JP) 2023-04-06 US disclosed
US-11541040-B2 Medicine for improving state of pregnancy, and use thereof Yamaguchi, Kouchi (JP) 2023-01-03 US disclosed
EP-3977995-A1 TACROLIMUS FOR AMELIORATING PREGNANCY CONDITIONS Yamaguchi, Koushi (JP) 2022-04-06 EP disclosed
EP-3900729-A1 AGENT FOR IMPROVING INFERTILITY, RECURRENT MISCARRIAGE, AND STATE OF PREGNANCY Yamaguchi, Koushi (JP) 2021-10-27 EP disclosed
EP-3246036-B1 MEDICINE FOR IMPROVING PREGNANCY-INDUCED HYPERTENSION SYNDROME YAMAGUCHI KOUSHI (JP) 2021-10-13 EP disclosed
CN-113226331-A Medicine for improving infertility or pregnancy state 山口晃史 2021-08-06 CN disclosed
US-20210228551-A1 THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN MATERNOFETAL RELATIONSHIP YAMAGUCHI KOUSHI (JP) 2021-07-29 US disclosed
EP-3834826-A1 THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN MATERNO-FETAL RELATIONSHIP Yamaguchi, Koushi (JP) 2021-06-16 EP disclosed
CN-112533599-A Therapeutic agent for humoral immunity-related diseases in maternal-fetal relationship 山口晃史 2021-03-19 CN disclosed
CN-107106588-B Agent for improving pregnancy status and use thereof 山口晃史 2020-08-11 CN disclosed
EP-0483842-A1 Pharmaceutical compositions containing tricyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-05-06 EP disclosed
US-5110811-A Antibody inhibitors FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1992-05-05 US disclosed
EP-0474126-A1 Ointments containing tricyclic compound FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-03-11 EP disclosed
WO-1992000313-A1 TRICYCLO COMPOUNDS, A PROCESS FOR THEIR PRODUCTION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-01-09 WO disclosed
WO-1991019495-A1 USE OF A MACROLIDE COMPOUND SUCH AS FK 506 FOR MANUFACTURING A MEDICAMENT FOR TREATING IDIOPATHIC THROMBOCYTOPENIC PURPURA AND BASEDOW'S DISEASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-12-26 WO disclosed
WO-1991017754-A1 METHODS FOR TREATING AND PREVENTING INFLAMMATION OF MUCOSA AND BLOOD VESSELS USING FK 506 AND RELATED COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-11-28 WO disclosed
EP-0444659-A2 A pharmaceutical solution comprising derivatives of FK506 FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-09-04 EP disclosed
EP-0423714-A2 Hair revitalizing agent FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-04-24 EP disclosed
EP-0406791-A2 Aqueous liquid composition for external use FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-01-09 EP disclosed
US-4929611-A ANTIBODY INHIBITORS FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1990-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103337-A1 MEDICINE FOR IMPROVING STATE OF PREGNANCY, AND USE THEREOF PGF, SLC10A1, SLC26A4 GPR84 1344/4885PPARG 678/4885PPARD 2288/4885
US-11541040-B2 Medicine for improving state of pregnancy, and use thereof PGF, SLC10A1, SLC26A4 GPR84 1217/4885PPARG 524/4885PPARD 1761/4885
US-20210228551-A1 THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN MATERNOFETAL RELATIONSHIP PGF, HAMP, HLA-DRB1 GPR84 4797/4885PPARG 4340/4885PPARD 4613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.